Looks like the fat lady has not yet sung on AZD4320, page-30

Starpharma makes bank interview with JF posted 14 August 2023. The interview touches on AZ's decision to discontinue the AZD0466 program (at the time trialling against leukaemia). At the 7 minute mark of the interview JF mentions that the 'product' also has had very interesting results with solid tissue tumors.

Could these solid tissue tumor resukts lead to something else? ... time will tell.

There still seems so much potential to be released as each week passes. Will a licencing deal be struck for one of the DEP products, will there be another Medicxi/Petalion type deal, SPL7013 product updates and an (official) update from TGA on Viraleze in Australia.

In the meantime, the following interview with the new CEO is a great listen on SPL's lasted strategic partnership, and provides some reassurance to shorter time frames than big pharma is capable of - you can see it here ... Breaking new ground via an oncology treatment tech venture